https://sms.carm.es/ricsmur/handle/123456789/17867 2026-05-27T16:17:14Z 2026-05-27T16:17:14Z Moreno-Egea, Alfredo Moreno-Latorre, Carlos Moreno-Latorre, Alfredo https://sms.carm.es/ricsmur/handle/123456789/26525 2026-05-13T11:04:54Z 2025-01-01T00:00:00Z

La Verdadera Historia de la Anatomía Perdida de Eustaquio (1520-1574) y sus Implicaciones Temporales Moreno-Egea, Alfredo; Moreno-Latorre, Carlos; Moreno-Latorre, Alfredo

2025-01-01T00:00:00Z Moreno-Egea, Alfredo Moreno-Latorre, Carlos Moreno-Latorre, Alfredo https://sms.carm.es/ricsmur/handle/123456789/26524 2026-05-13T11:04:54Z 2025-01-01T00:00:00Z

Análisis Contextual del Plagio más Famoso de la Historia de la Medicina: Govard Bidloo versus William Cowper Moreno-Egea, Alfredo; Moreno-Latorre, Carlos; Moreno-Latorre, Alfredo

2025-01-01T00:00:00Z Pastor-Cano, Josep Aranda-García, Ana Gascón-Cánovas, Juan-José Rausell-Rausell, Víctor-José Tobaruela-Soto, Mariana https://sms.carm.es/ricsmur/handle/123456789/26521 2026-05-13T11:04:53Z 2017-01-01T00:00:00Z

Criterios Beers versus STOPP. Posibles implicaciones de la adaptación española de los criterios de Beers Pastor-Cano, Josep; Aranda-García, Ana; Gascón-Cánovas, Juan-José; Rausell-Rausell, Víctor-José; Tobaruela-Soto, Mariana

2017-01-01T00:00:00Z Pacheco-López, Pilar Meroño-Saura, María-Antonia Aranda-García, Ana https://sms.carm.es/ricsmur/handle/123456789/26518 2026-05-13T11:04:49Z 2021-01-01T00:00:00Z

Uso de Ataluren en españa: incoherencias administrativas y aspectos éticos implicados Pacheco-López, Pilar; Meroño-Saura, María-Antonia; Aranda-García, Ana Duchenne muscular dystrophy is a rare genetic disease with only ataluren like pharmaceutical treatment available. This drug received a conditional authorization by the European Medicines Agency (EMA) in 2014, meaning that it was commercially available while waiting for more solid results that demonstrate the efficacy and safety. Currently, the authorization still maintains the "conditional" modality, and the actual health benefits of the drug still remain unclear. In Spain, ataluren is not financed by the National Health System. The decision of non-financing has generated a heated debate, especially because in those patients who se treatment were started prior to the non-financing decision the drug has continued being funded. This controversial situation encompasses complex aspects of pharmaceutical and health management related to scientific evidence, the motivations of regulatory agencies and the pharmaceutical industry in the processes of drug investigation and authorization. Furthermore, as the center of the debate, some pillars of bioethics such as justice and equity, as well as certain legal principles, such as the protection of minors, are involved.

2021-01-01T00:00:00Z